Sanjay Gupta is Carter Kissell Associate Professor & Research Director in the Department of Urology at the Case Western Reserve University and University Hospitals Cleveland Medical Center. He also holds secondary appointments in the Departments of Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center. Dr. Gupta obtained faculty position in 2002 at Case, School of Medicine.
Dr. Gupta has authored some 80 publications, including book chapters, research articles and reviews, and has spoken at several occasions in cancer prevention symposium, seminars and meetings. He has been serving in various study sections at National Cancer Institute (NCI) and Department of Defense (DOD) and reviewer for several prestigious scientific journals. His research programs have received support from National Cancer Institute, National Center for Complementary and Alternative Medicine and Cancer Research and Prevention Foundation. His innovative approach to develop these agents in the prevention and treatment of prostate cancer has led to publications in several journals including Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Sciences, USA, Journal of Clinical Oncology, FASEB Journal and has been featured on NBC-5 news and highlighted in the Plain Dealer, and American Association for Cancer Research press release.
- Biomarkers of prostate cancer
- Chemoprevention of prostate cancer by naturally occurring or synthetic compounds
- Epigenetic mechanisms of gene silencing in prostate cancer
- Identification and characterization of prostate tumor stem cells
- Molecular mechanisms of prostate cancer
- Molecular targets of prostate cancer
- Prevention-based clinical trials with promising agents
- Role of Inflammation in promoting prostate cancer
- Stem cells as therapeutics in prostate cancer
Dr. Sanjay Gupta's research is primarily on prostate cancer and involves both basic and translational areas of focus. In basic research the focus is to develop appropriate biomarkers for early detection and prognosis of prostate cancer. Another focus is to identify novel targets to monitor the efficacy of treatment with chemopreventive or therapeutic agents. His research interests also include translation of bench research to its application in clinics. With this aim he has been working with bioactive dietary agents which could be developed as future chemopreventives.
Dr. Gupta has ongoing interest in green tea polyphenols to be developed as chemopreventive agent for prostate cancer. These studies were initiated in cell culture which further progressed in testing the efficacy in pre-clinical models of prostate cancer. More recently some of the issues related to bioavailability of the test agent in target tissue and biomarkers monitoring the course of disease are being addressed through a phase II clinical trial with green tea polyphenols.